Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 79,351 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Diabetes
Interventions: Standard ONS, Diabetes specific ONS 1, Diabetes specific ONS 2; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • Cincinnati, Ohio

Conditions: Familial Partial Lipodystrophy, Metabolic Abnormalities
Interventions: REGN4461, Matching Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Boca Raton, Florida • Bethesda, Maryland • Ann Arbor, Michigan + 2 more

Conditions: Headaches Associated With Subarachnoid Hemorrhage (SAH)
Interventions: Low dose fentanyl PCA, Standard IV fentanyl bolus; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Uncontrolled Gout, Kidney Transplant
Interventions: Pegloticase; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 5 more

Conditions: Fetal Lung Maturity, Respiratory Distress Syndrome in Premature Infant
Interventions: blood draw; Other
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 80 participants
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Depression, Anxiety, Cancer
Interventions: Mood Triggers App; Other
Lead sponsor: Trustees of Dartmouth College; Other
Eligibility: 40 Years to 64 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Hanover, New Hampshire

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 114
States / cities: Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions: BPX-501 dose 1, Rimiducid, BPX-501 dose 2, BPX-501 dose 3, BPX-501 dose 4, SCT; Biological · Drug · Procedure
Lead sponsor: Bellicum Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2032
U.S. locations: 8
States / cities: Atlanta, Georgia • Buffalo, New York • New York, New York + 4 more

Conditions: Multiple Myeloma
Interventions: Velcade, Melphalan, Prednisone, Daratumumab IV, Dexamethasone, Daratumumab SC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 10
States / cities: California City, California • Corona, California • Fountain Valley, California + 7 more

Conditions: SARS-CoV-2
Interventions: mRNA-1283, mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Chandler, Arizona • San Diego, California • Melbourne, Florida + 2 more

Conditions: Food Insecurity
Interventions: Produce prescription program, Grocery store gift cards; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
Interventions: RIC regimen, GVHD prophylaxis regimen; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Day to 21 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2033
U.S. locations: 4
States / cities: New Haven, Connecticut • Wilmington, Delaware • Grand Rapids, Michigan + 1 more

Conditions: Stigma, Social, Mental Health Issue
Interventions: Stigma-reduction intervention; Behavioral
Lead sponsor: Harvard University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteosarcoma Metastatic, Ewing's Sarcoma Metastatic
Interventions: Chemotherapy (gemcitabine & docetaxel) plus BIO-11006; Drug
Lead sponsor: Nicklaus Children's Hospital f/k/a Miami Children's Hospital; Other
Eligibility: 5 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions: Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice; Drug · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Herpes Zoster Keratitis
Interventions: gancyclovir gel, Hypromellose gel; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Crohn Disease
Interventions: RoadMAB, Infliximab; Device · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 22 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 8 more

Conditions: Breast Cancer
Interventions: cyclophosphamide, doxorubicin hydrochloride, paclitaxel; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 18
States / cities: Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more

Conditions: Cancer
Interventions: Standardized Meals for Diet Stabilization, Forticare, Product 4808; Behavioral · Dietary Supplement
Lead sponsor: University of Arkansas; Other
Eligibility: 40 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Depressive Disorder, Major, Asthma
Interventions: Lexapro; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 175 participants
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypovolemia
Interventions: Kedbumin 25%, Normal Saline Solution; Drug
Lead sponsor: Kedrion S.p.A.; Industry
Eligibility: Up to 12 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 2
States / cities: Louisville, Kentucky • Milwaukee, Wisconsin

Conditions: Pain, Postoperative
Interventions: Acetaminophen Intravenous, Acetaminophen Oral; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Critical Illness, Enteral Nutrition, Enteral Feeding Intolerance
Interventions: TAK-954, Metoclopramide, Normal Saline; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 14
States / cities: Augusta, Georgia • Idaho Falls, Idaho • Peoria, Illinois + 11 more

Conditions: Brain Metastases, HR+ Metastatic Breast Cancer
Interventions: Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Columbus, Ohio

Search by objective public record fields.

Effect of Nutritional Products in Subjects With Type 2 Diabetes

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

Randomized Trial for Pain Management in Low-grade Subarachnoid Hemorrhage

Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant

Effect of Steroid Administration on Maternal Blood Levels of hLPCAT1 mRNA

Using a Smartphone App to Target Current Mental Health Symptoms of Anxiety and Depression

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

Reducing Food Insecurity During COVID-19

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Brief Interventions on Social Media to Reduce Suicide Risk (Intervention 2)

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis

Precise Infliximab Exposure and Pharmacodynamic Control

Combination Chemotherapy in Treating Patients With Breast Cancer

Effects of Nutritional Supplementation (Product 4808) on Acute Skeletal Muscle Protein Synthesis in Cancer Patients

Impact of Caregiver Depression on Asthma in the Child

Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients

Intravenous Versus Oral Acetaminophen for Postoperative Pain Control After Cesarean Delivery

TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)

SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases